美國國立衛(wèi)生研究院致力于加速COVID-19治療的發(fā)展

美國國立衛(wèi)生研究院致力于加速COVID-19治療的發(fā)展

In an bid to help speed up the development of potential treatment options and a vaccine for COVID-19. the National Institutes of Health on Friday announced a new public-private research partnership.

為了幫助加速開發(fā)潛在的治療方案和COVID-19疫苗，美國國立衛(wèi)生研究院上周五宣布了一項(xiàng)新的公私合作研究伙伴計(jì)劃。

The new initiative will be spearheaded by the NIH but also include the Food and Drug Administration, other parts of the federal government and a list of 16 companies that includes some of the biggest players in the pharmaceutical industry.

這項(xiàng)新計(jì)劃將由美國國立衛(wèi)生研究院(NIH)牽頭，但也包括美國食品和藥物管理局、聯(lián)邦政府的其他部門，以及一份由16家公司組成的名單，其中包括一些最大的制藥行業(yè)。

Among the companies participating in the effort are Pfizer, Johnson & Johnson and Merck.

參與這項(xiàng)工作的公司包括輝瑞、強(qiáng)生和默克。

"We need to have all hands on deck from every sector to speed up the process of identifying those treatments that are going to work and to get the vaccines also developed, tested, to make sure they're safe and effective in the maximum possible speed," said Dr. Francis Collins, director of the NIH, in an interview with NPR's All Things Considered.

美國國立衛(wèi)生研究院院長弗朗西斯·柯林斯博士在接受美國國家公共廣播公司《綜合考慮》采訪時(shí)說：“我們需要各個(gè)部門的全體人員，加快確定那些有效治療方法的進(jìn)程，并讓疫苗也得到開發(fā)、測試，以確保它們以盡可能快的速度安全有效。”

The announcement comes after President Trump and public health officials on Thursday unveiled new guidelines for states to begin reopening the country.

周四，特朗普總統(tǒng)和公共衛(wèi)生官員公布了重啟美國的新指導(dǎo)方針。

Health experts say that in order to safely do that, there needs to be more testing, contact tracing and better drugs to treat COVID-19. Ultimately, for things to truly return to normal, an effective vaccine is needed.

衛(wèi)生專家說，為了安全起見，需要進(jìn)行更多的檢測、追蹤接觸者以及更好的藥物來治療COVID-19.最終，要使一切真正恢復(fù)正常，就需要一種有效的疫苗。

Collins said there are already two vaccines in phase one trials, and behind that, a series of more than 40 other vaccines being developed as well. But he cautioned that the public should expect failures along the way.

柯林斯說，目前已經(jīng)有兩種疫苗處于第一階段的試驗(yàn)階段，在此之后，還有40多種其他疫苗也在研發(fā)中。但他警告說，公眾應(yīng)該預(yù)料到會(huì)有失敗。

Collins also provided an update on testing of antiviral drug, remdesivir, and shared his thoughts on Dr. Anthony Fauci, the high-profile director of the National Institute of Allergy and Infectious Diseases.

柯林斯還介紹了抗病毒藥物雷姆德西韋的最新測試情況，并分享了他對(duì)美國國家過敏和傳染病研究所知名所長安東尼·福奇博士的看法。

Here are excerpts from the conversation.

以下是對(duì)話的節(jié)選。

There's a lot of buzz about an antiviral called remdesivir.

關(guān)于一種叫做雷姆德西韋的抗病毒藥物有很多傳言。

Remdesivir is certainly, I think, at the top of most people's hopeful list, but not yet proven. We're running a human trial with now 800 participants enrolled more quickly than expected. We will know, I think, in the next two to four weeks whether it worked or not.

我認(rèn)為，雷姆德西韋肯定是大多數(shù)人希望的首選藥物，但還沒有得到證實(shí)。我們正在進(jìn)行一項(xiàng)人體試驗(yàn)，現(xiàn)在有800名參與者加入，比預(yù)期的要快。我想，在接下來的兩到四周內(nèi)，我們將會(huì)知道它是否有效。